Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1598-1605

  Page, Stephanie T ^a   Krauss, Ronald M ^b   Gross, Coleman ^c   Ishida, Brian ^d   Heinecke, Jay W ^a   Tang, Chongren ^a   Amory, John K ^a   Schaefer, Peter M ^d   Cox, Cheryl J ^d   Kane, John ^d,e   Purnell, Jonathan Q ^f   Weinstein, Richard L ^g   Vaisar, Tomaš ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^c Corcept Therapeutics Inc ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g Diablo Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CORTICOTROPIN; ESTRADIOL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIFEPRISTONE; PLACEBO; TESTOSTERONE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GLUCOSE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION;

AGED; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FEMALE; HORMONE ANTAGONISTS; HUMANS; LIPOPROTEINS, HDL; MIDDLE AGED; MIFEPRISTONE; POSTMENOPAUSE; PROGESTERONE;

EID: 84860779643     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2813     Document Type: Article

References (38)

1. Newell-Price J, Bertagn AX, Grossman AB, Nieman LK 2006 Cushing's syndrome. Lancet 367:1605-1617
2. Johanssen S, Allolio B 2007 Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 157:561-569
3. Brunzell JD, Hokanson JE 1999 Dyslipidemiaof central obesity and insulin resistance. Diabetes Care 22(Suppl 3):C10-C13
4. Taskinen MR, Nikkilä EA, Pelkonen R, Sane T 1983 Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab 57:619-626
5. Ettinger WH, Klinefelter HF, Kwiterovitch PO 1987 Effect of shortterm, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 63:167-172
6. Davidson WS, Thompson TB 2007 The structure of apolipoprotein A-I in high density lipoproteins. J Biol Chem 282:22249-22253
7. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N 2008 HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 7:365-375
8. Oram JF, Heinecke JW 2005 ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 85:1343-1372
9. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW 2007 Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117:746-756
10. Sorci-Thomas MG, Thomas MJ 2002 The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 12:121-128
11. Rosenson RS, Brewer Jr HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ 2011 HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57:392-410
12. Francis GA 2010 The complexity of HDL. Biochim Biophys Acta 1801:1286-1293
13. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM 1993 Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 365:762-764
14. Khera AV, Cuche LM, de la Llera-Moy AM, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ 2011 Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127-135
15. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH 2010 The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 30:796-801
16. Fleseriu M, Biller B MK, Findling JW, Molitch ME, Schteingart DE, Gross C, Mifepristo ne, a glucocorticoid receptor antagoni st, produces clinical and metabolic benefits in patients with refractory Cushing syndrome: results from the study of the efficacy and safety of mifepristone in the treatment of endogenous Cushing syndrome. Program of the 93rd Annual Meeting of the Endocrine Society, Boston, Massachusetts, 2011 (Abstract OR09-5)
17. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J 1989 Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49:2851-2856
18. Krauss RM 2010 Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 21:305-311
19. Guey LT, Pullinger CR, Ishida BY, O'Connor PM, Zellner C, Francone OL, Laramie JM, Naya-Vigne JM, Siradze KA, Deedwania P, Redberg RF, Frost PH, Seymour AB, Kane JP, Malloy MJ 2011 Relation of increased preβ-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol 108:360-366
20. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ 2004 High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24:2181-2187
21. Khera AV, Rader DJ 2009 Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics. Trends Cardiovasc Med 19:195-201
22. Watanabe H, Soderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, Alagona C, Salonen R, Tuomainen TP, Ehnholm C, Jauhiainen M, Taskinen MR 2006 Decreased high-density lipoprotein (HDL) particle size, preβ-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 26:897-902
23. Musunuru K, Orho-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, Berglund G, Hedblad B, Engstrom G, Williams PT, Kathiresan S, Melander O, Krauss RM 2009 Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol 29:1975-1980
24. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM 2009 Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119:931-939
25. Morgan J, Carey C, Lincoff A, Capuzzi D 2004 High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 6:359-365
26. Sharma M 2011 Combination therapy for dyslipidemia. Curr Opin Cardiol 26:420-423
27. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B 2007 Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122
28. Shao B, Oda MN, Oram JF, Heinecke JW 2010 Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 23:447-454
29. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM 2004 Antiinflammatory properties of HDL. Circ Res 95:764-772
30. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP 2009 Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 94:2692-2701
31. Wajchenberg BL, Bosco A, Marone MM, Levin S, Rocha M, Lerário AC, Nery M, Goldman J, Liberman B 1995 Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 80:2791-2794
32. Mayo-Smith W, Hayes CW, Biller BM, Klibanski A, Rosenthal H, Rosenthal DI 1989 Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology 170:515-518
33. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS 2001 Atransgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170
34. Saladin R, Vu-Dac N, Fruchart JC, Auwerx J, Staels B 1996 Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein. Eur J Biochem 239:451-459
35. Staels B, van Tol A, Cha NL, Verhoeven G, Auwerx J 1991 Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats. Arterioscler Thromb 11:760-769
36. Mahley RW, Gray ME, Hamilton RL, Le Quire VS 1968 Lipid transport in liver. II. Electron microscopic and biochemical studies of alterations in lipoprotein transport induced by cortisone in the rabbit. Lab Invest 19:358-369
37. Knopp RH, Zhu X 1997 Multiple beneficial effects of estrogen on lipoprotein metabolism. J Clin Endocrinol Metab 82:3952-3954
38. Berg AL, Nilsson-Ehle P 1994 Direct effects of corticotropin on plasma lipoprotein metabolism inman-studiesin vivo and in vitro. Metabolism 43:90-97